^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sirolimus

    i
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    Apply
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2029
    ALK • HLA-B • HLA-C
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (NCT00792948)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2016
    Completion :
    01/06/2026
    ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/23/2021
    Primary completion :
    04/27/2027
    Completion :
    04/30/2027
    EGFR • IGH
    |
    cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
    Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    08/24/2017
    Primary completion :
    12/01/2021
    Completion :
    12/02/2021
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
    Optimizing PTCy Dose and Timing (NCT03983850)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/09/2019
    Primary completion :
    05/31/2025
    Completion :
    05/29/2026
    KRAS • PTEN • IGH • FBXW7
    |
    KRAS mutation • RAS mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous
    211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    10/24/2017
    Primary completion :
    06/30/2027
    Completion :
    03/31/2029
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    sirolimus • fludarabine IV • cyclosporin A microemulsion
    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant (NCT04177004)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/30/2021
    Primary completion :
    10/27/2025
    Completion :
    10/27/2025
    HLA-DRB1
    |
    cyclophosphamide • etoposide IV • sirolimus • Kepivance (palifermin)
    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCI-2017-01311) (NCT03246906)
    Phase 2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/11/2017
    Primary completion :
    05/03/2025
    Completion :
    05/03/2025
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous
    211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCI-2018-01788) (NCT03670966)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    07/10/2019
    Primary completion :
    06/28/2027
    Completion :
    03/20/2029
    HLA-DRB1 • HLA-B
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous
    UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies (NCT06743503)
    Phase 1
    Nanjing IASO Biotechnology Co., Ltd.
    Not yet recruiting
    Last update posted :
    12/20/2024
    Initiation :
    12/31/2024
    Primary completion :
    05/21/2028
    Completion :
    07/31/2030
    CD20 • CD8 • CD4 • NCAM1 • FOXP3
    |
    sirolimus
    Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    09/24/2015
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C
    |
    Chr t(9;11)
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • sirolimus • fludarabine IV • Kepivance (palifermin)
    Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (NCT05896839)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    08/11/2024
    Primary completion :
    01/31/2027
    Completion :
    01/31/2027
    BRAF
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)
    Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (NCT06437574)
    Phase 2
    Cedars-Sinai Medical Center
    Not yet recruiting
    Last update posted :
    06/05/2024
    Initiation :
    07/01/2024
    Primary completion :
    02/29/2028
    Completion :
    05/31/2028
    CD8
    |
    sirolimus • ezetimibe/simvastatin
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (NCT05436418)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    11/18/2022
    Primary completion :
    06/25/2027
    Completion :
    07/02/2027
    IGH • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (NCI-2019-03188) (NCT03970096)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    11/19/2019
    Primary completion :
    12/31/2026
    Completion :
    12/31/2028
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV
    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (NCT01163357)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/28/2011
    Primary completion :
    07/20/2019
    Completion :
    12/31/2024
    HLA-DRB1
    |
    Chr del(17p)
    |
    bortezomib • sirolimus • melphalan • fludarabine IV
    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCI-2017-01069) (NCT03192397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/09/2017
    Primary completion :
    08/21/2023
    Completion :
    05/21/2027
    HLA-DRB1
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous
    Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens (NCT01428973)
    Phase 2
    University of Liege
    Active, not recruiting
    Last update posted :
    05/09/2024
    Initiation :
    09/01/2011
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    HLA-DRB1 • HLA-B • HLA-C
    |
    sirolimus
    Allo HSCT Using RIC and PTCy for Hematological Diseases (NCT05805605)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    05/01/2023
    Primary completion :
    10/22/2027
    Completion :
    10/22/2028
    NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV
    PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation (NCT05120570)
    Phase 1/2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    03/17/2022
    Primary completion :
    03/31/2025
    Completion :
    03/31/2028
    CD4
    |
    sirolimus • VIC-1911
    Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (NCT00544115)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    04/02/2024
    Initiation :
    10/16/2001
    Primary completion :
    03/13/2007
    Completion :
    12/30/2024
    HLA-DRB1 • HLA-B
    |
    cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan • cyclosporine • cyclophosphamide intravenous
    A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    03/25/2024
    Initiation :
    06/08/2017
    Primary completion :
    01/28/2022
    Completion :
    04/18/2022
    IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C
    |
    sirolimus • Vonjo (pacritinib)
    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    02/10/2014
    Primary completion :
    12/27/2019
    Completion :
    12/30/2024
    HLA-B • HLA-C
    |
    sirolimus • clofarabine • melphalan
    Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (NCT01203722)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    09/01/2010
    Primary completion :
    09/01/2025
    Completion :
    12/01/2025
    FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)
    |
    cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
    Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911)
    Phase 1
    Zachariah Michael DeFilipp
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    08/14/2020
    Primary completion :
    10/22/2023
    Completion :
    10/01/2024
    HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV
    PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML (NCT05105152)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    03/04/2024
    Initiation :
    11/29/2021
    Primary completion :
    02/28/2026
    Completion :
    01/31/2041
    CD33
    |
    sirolimus • DARIC33
    Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors (AflacST1502) (NCT02574728)
    Phase 2
    Emory University
    Recruiting
    Last update posted :
    02/23/2024
    Initiation :
    06/01/2015
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    AFP
    |
    cyclophosphamide • etoposide IV • sirolimus • celecoxib oral • cyclophosphamide intravenous
    A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan (NCT00577278)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    02/16/2024
    Initiation :
    10/03/2007
    Primary completion :
    05/30/2019
    Completion :
    12/14/2023
    CD20
    |
    Rituxan (rituximab) • sirolimus • melphalan • fludarabine IV • Zevalin (ibritumomab tiuxetan)
    SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors (NCT03433183)
    Phase 2
    Sarcoma Alliance for Research through Collabora...
    Completed
    Last update posted :
    12/25/2023
    Initiation :
    10/02/2019
    Primary completion :
    06/22/2022
    Completion :
    10/01/2023
    NF1
    |
    Koselugo (selumetinib) • sirolimus
    Efficacy and Safety of Sirolimus in LAM (MILES) (NCT00414648)
    Phase 3
    University of Cincinnati
    Completed
    Last update posted :
    11/02/2023
    Initiation :
    12/01/2006
    Primary completion :
    09/01/2010
    Completion :
    02/01/2011
    VEGFD
    |
    sirolimus
    Cryopreserved MMUD BM With PTCy for Hematologic Malignancies (PRESERVE) (NCT05170828)
    Phase 1
    Ossium Health, Inc.
    Withdrawn
    Last update posted :
    11/01/2023
    Initiation :
    09/01/2022
    Primary completion :
    03/01/2024
    Completion :
    11/01/2024
    CD8 • HLA-DRB1 • CD4
    |
    cyclophosphamide • sirolimus • fludarabine IV • mesna • busulfan • Neupogen (filgrastim)
    Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02975882)
    Phase 1
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    10/06/2023
    Initiation :
    08/15/2017
    Primary completion :
    03/31/2022
    Completion :
    09/22/2024
    AFP
    |
    temozolomide • irinotecan • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
    A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis (NCT01265030)
    Phase 1/2
    MaineHealth
    Completed
    Last update posted :
    06/26/2023
    Initiation :
    02/01/2014
    Primary completion :
    12/22/2021
    Completion :
    12/22/2021
    APC
    |
    APC mutation
    |
    sirolimus
    Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy (NCT03217669)
    Phase 1
    Chao Huang
    Active, not recruiting
    Last update posted :
    05/02/2023
    Initiation :
    02/22/2018
    Primary completion :
    04/01/2024
    Completion :
    08/01/2025
    EGFR • ALK
    |
    EGFR mutation • EGFR T790M
    |
    sirolimus • epacadostat (INCB024360)
    RAPA-201 Therapy of Solid Tumors (NCT05144698)
    Phase 1/2
    Rapa Therapeutics LLC
    Recruiting
    Last update posted :
    03/30/2023
    Initiation :
    08/01/2021
    Primary completion :
    01/01/2024
    Completion :
    12/31/2024
    EGFR • ALK • BRCA
    |
    EGFR mutation • ALK translocation • BRCA mutation
    |
    carboplatin • paclitaxel • Torisel (temsirolimus) • sirolimus • RAPA-201
    UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    02/24/2023
    Initiation :
    05/15/2017
    Primary completion :
    02/22/2023
    Completion :
    12/01/2029
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
    A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia (NCT01756118)
    Phase 1
    Goethe University
    Completed
    Last update posted :
    02/16/2023
    Initiation :
    06/01/2012
    Primary completion :
    12/01/2017
    Completion :
    02/07/2020
    ABL1 • BCR
    |
    dactolisib (RTB101) • sirolimus
    Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (NCT03253913)
    Phase 2
    University of Cincinnati
    Completed
    Last update posted :
    02/01/2023
    Initiation :
    03/31/2018
    Primary completion :
    10/15/2022
    Completion :
    10/15/2022
    VEGFD
    |
    sirolimus
    Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT00995059)
    Phase 1/2
    Mayo Clinic
    Withdrawn
    Last update posted :
    01/05/2023
    HLA-DRB1
    |
    Chr t(14;16)
    |
    bortezomib • sirolimus • melphalan